A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins
April 30th, 2018
7.3K views
Here, we present a method to engineer the genome of C. elegans using CRISPR-Cas9 ribonucleoproteins and homology dependent repair templates.
Overview
This article presents a method for engineering the genome of C. elegans using CRISPR-Cas9 ribonucleoproteins and homology dependent repair templates. This technique allows for the rapid generation of genomic point mutations, facilitating the functional study of genetic variance in the context of endogenous regulatory control.
Key Study Components
Area of Science
- Neuroscience
- Genetics
- CRISPR Technology
Background
- C. elegans is a model organism widely used in genetic studies.
- Understanding genetic variance is crucial for insights into neurodegenerative diseases.
- CRISPR-Cas9 technology enables precise genome editing.
- Homology directed repair templates are essential for generating specific mutations.
Purpose of Study
- To generate genomic point mutations in C. elegans.
- To investigate the pathological consequences of genetic variance.
- To enhance the understanding of neurodegenerative diseases.
Methods Used
- Utilization of CRISPR-Cas9 ribonucleoproteins.
- Application of single stranded oligonucleotide homology directed repair templates.
- Selection of sgRNA targets based on specific genomic sequences.
- Rapid generation of mutations for functional studies.
Main Results
- Successful generation of genomic point mutations in C. elegans.
- Facilitated functional studies of genetic variance.
- Demonstrated the advantages of avoiding protein overexpression.
- Provided a protocol for sgRNA target selection.
Conclusions
- This method offers a rapid approach to genome editing in C. elegans.
- It aids in understanding the genetic basis of neurodegenerative diseases.
- The technique can be applied to various genetic studies.
Frequently Asked Questions
What is the main advantage of using CRISPR-Cas9 in C. elegans?
The main advantage is the rapid generation of genomic point mutations, allowing for functional studies without the complications of protein overexpression.
How does this method contribute to neuroscience research?
It helps in determining the pathological consequences of genetic variance associated with neurodegenerative diseases.
What are homology directed repair templates?
They are single stranded oligonucleotides used to guide the repair of DNA during the genome editing process.
Can this method be used for other organisms?
While this method is specifically designed for C. elegans, similar CRISPR techniques can be adapted for other organisms.
What is the role of sgRNA in this process?
sgRNA is used to guide the CRISPR-Cas9 complex to the specific genomic location for editing.
Is there a specific protocol for selecting sgRNA targets?
Yes, the protocol involves inputting a sequence flanking the desired edit into a designated webpage for target selection.
Executive Industry Relevance
This method enables rapid generation of precise genomic point mutants in C. elegans, supporting target validation and mechanistic de-risking in neuroscience and genetic disease research. By avoiding protein overexpression artifacts, it provides physiologically relevant models for studying neurodegenerative disease variants. The workflow delivers edited animals in 4-5 days, accelerating early discovery timelines and reducing screening burden.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by introducing specific disease-associated variants like human G93A SOD1 into endogenous loci.
- Operational Value: Facilitates biological de-risking through precise genome editing under native regulatory control.
- Predictive Value: Supports portfolio triage by generating isogenic models for functional assessment of genetic variance.
Screening & Assay Development
- Scientific Value: Produces validated biological systems with defined point mutations for downstream phenotypic screening.
- Operational Value: Enables assay standardization via mCherry enrichment strategy that increases editing efficiency and reduces false negatives.
- Scalability: Supports platform reuse through modular sgRNA and HDR template design for diverse targets.
Translational & Preclinical Research
- Translational Continuity: Generates disease-relevant models that bridge discovery to preclinical validation of neurodegenerative targets.
- Mechanistic De-risking: Allows assessment of pathological consequences of genetic variance in physiologically relevant context.
- Risk-Adjusted Advancement: Enables early phenotype linkage to genetic edits, informing go/no-go decisions.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target identification to lead optimization, providing genetically defined models for hypothesis testing and compound evaluation.
- Discovery Biology: Supports hypothesis testing and pathway clarification via precise editing of disease-relevant genes like SOD1.
- Screening: Delivers assay-ready models with quantitative genotyping outputs (restriction digest, Sanger sequencing) for reliable compound evaluation.
- Analytics: Enables comparison of edited vs. wild-type animals through PCR-based genotyping and fragment analysis.
- Translational Research: Connects to preclinical work by creating isogenic models that reflect human genetic variants.
- Enterprise Reuse: Establishes a modular pipeline for rapid generation of point mutants across multiple targets.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence through physiologically relevant models; reduction of mechanistic ambiguity via endogenous expression.
- Operational Value: Standardization via RNP delivery and HDR template design; reproducibility through enriched F1 screening.
- Strategic Value: Better go/no-go decisions via early phenotype-genotype linkage; capital efficiency from reduced screening workload.
- Portfolio Impact: Risk-adjusted prioritization through rapid generation of allelic series for target validation.
Implementation Considerations
- Requires expertise in CRISPR design, microinjection, and molecular genotyping.
- Depends on access to microinjection equipment, thermocycler, and gel electrophoresis systems.
- Necessitates standardization of sgRNA and HDR template workflows across teams.
- Adaptation considerations include homology arm length and silent mutation design for different targets.
- Practical limitation: Efficiency depends on effective delivery and HDR rates in germline.
Biopharma FAQs
Why does restriction enzyme digestion confirm editing?
Restriction enzyme digestion detects the unique in-frame site introduced by the HDR template, enabling rapid identification of edited animals via gel-based fragment analysis.
How does mCherry enrichment improve editing efficiency?
Co-injection of mCherry-expressing plasmid enriches for injected progeny, increasing the proportion of genome-edited F1 animals and reducing screening workload.
What enables detection of indel alleles during screening?
Agarose gel separation of restriction-digested PCR products reveals aberrant band patterns indicative of indel modifications alongside desired edits.
Why is Sanger sequencing required after gel extraction?
Sanger sequencing of gel-extracted PCR products confirms precise nucleotide incorporation from the HDR template, validating homozygous edits.
What supports cross-functional reproducibility?
Standardized RNP complexing, injection protocols, and genotyping workflows ensure consistent results across users and laboratories.
Chapters in this video
0:04
Title
0:42
sgRNA Target Selection and Homology-directed Repair Template Design
2:21
Prepare Injection Mix and Injection Protocol
3:18
Screen P0 Plates and Single mCherry(+) F1s
4:03
Single Worm PCR and Genotyping
5:41
Indentification and Sequence Verification of Edited Animals
6:34
Results: Rapid CRISPR/Cas9 Generated Point Mutations in C. elegans sod-1
7:50
Conclusion
